David Baltimore
76Patents
12h-index
70Co-inventors
87Inventor score
Filing activity: Nov 12, 1981 → Jul 16, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6410516B1 | Nuclear factors associated with transcriptional regulation | Physics | 95 | Expired |
| US5804374A | Nuclear factors associates with transcriptional regulation | Physics | 46 | Expired |
| US7195916B2 | Method for expression of small antiviral RNA molecules within a cell | Chemistry; Metallurgy | 38 | Expired |
| US4719177A | Production of complementary DNA representing RNA viral sequences by recombinant DNA methods and uses therefor | Emerging Cross-Sectional Technologies | 36 | Expired |
| US6150090A | Nuclear factors associated with transcriptional regulation | Physics | 31 | Expired |
| US8119772B2 | MART-1 T cell receptors | Human Necessities | 29 | Active |
| US7323619B2 | Method for producing transgenic birds and fish | Emerging Cross-Sectional Technologies | 27 | Expired |
| US7939059B2 | Method for the generation of antigen-specific lymphocytes | Chemistry; Metallurgy | 26 | Active |
| US9527904B2 | Delivery of proteins using adeno-associated virus (AAV) vectors | Chemistry; Metallurgy | 21 | Active |
| US8865881B2 | Delivery of proteins using adeno-associated virus (AAV) vectors | Chemistry; Metallurgy | 18 | Active |
| US9540657B2 | Expression of secreted and cell-surface polypeptides | Chemistry; Metallurgy | 15 | Active |
| US5674680A | Methods for the prognosis and monitoring of AIDS | Chemistry; Metallurgy | 12 | Expired |
| US7737124B2 | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell | Emerging Cross-Sectional Technologies | 12 | Active |
| US7732193B2 | Method for expression of small RNA molecules within a cell | Emerging Cross-Sectional Technologies | 11 | Expired |
| US7732207B2 | Method for expression of small antiviral RNA molecules within a cell | Emerging Cross-Sectional Technologies | 11 | Active |
| US5516630A | Methods of detecting hepatitis A virus | Emerging Cross-Sectional Technologies | 11 | Expired |
| US8821856B2 | Method of targeted gene delivery using viral vectors | Emerging Cross-Sectional Technologies | 11 | Active |
| US8329162B2 | Targeted gene delivery for dendritic cell vaccination | Emerging Cross-Sectional Technologies | 9 | Active |
| US6159731A | Daxx, a Fas-binding protein that activates JNK and apoptosis | Human Necessities | 9 | Expired |
| US8361982B2 | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell | Emerging Cross-Sectional Technologies | 8 | Active |
| US5919458A | Non-infectious HIV particles and uses therefor | Emerging Cross-Sectional Technologies | 8 | Expired |
| US6916917B1 | Chimeric pro-caspases and methods of using same | Chemistry; Metallurgy | 8 | Expired |
| US7919309B2 | Method for expression of small antiviral RNA molecules within a cell | Emerging Cross-Sectional Technologies | 7 | Expired |
| US9303072B2 | Method of stimulating an immune response using a pseudotyped lentivirus | Emerging Cross-Sectional Technologies | 7 | Active |
| US5358856A | Gene expression in mammalian cells using a cap independent 5' noncoding region | Chemistry; Metallurgy | 7 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.